Whole genome sequencing (WGS) has emerged as a powerful tool to facilitate the study of existing and emerging infectious diseases. WGS-based genomic surveillance provides information on the genetic diversity and tracks the evolution of important viral pathogens, including respiratory syncytial virus (RSV). Multiplex tiling polymerase chain reaction (PCR) assays have been used to facilitate sequencing of a variety of pathogens in support of genomics-based surveillance initiatives. We developed, optimized, and implemented multiplex tiling PCR assays for RSVA and RSVB capable of generating near-complete genomes in the majority of contemporaneous specimens tested. A pilot data set comprising 52 RSVA and 37 RSVB genomes derived from Canadian clinical specimens during the 2022–2023 respiratory virus season was used to perform phylogenetic analyses using both near-complete genome and glycoprotein (G) sequences. Overall, the RSV phylogenetic tree built with whole genomes showed identical lineage clusters as compared to the G gene but was more discriminatory. Moreover, the availability of complete genomes enables the identification of a broader range of mutations. For instance, mutations identified in the fusion protein among Canadian isolates tested here, including S377N, K272M, S276N, S211N, S206I, and S209Q, could affect the efficacy of current vaccines or antiviral-based therapeutics. In conclusion, our work reinforces other recent studies demonstrating the utility of multiplex tiling PCR assays to facilitate high-throughput WGS of RSV, which is capable of supporting enhanced genomic surveillance initiatives, as well as the more comprehensive genomic analyses required to inform public health strategies for the development and usage of vaccines and antiviral drugs. IMPORTANCE: We present assays to efficiently sequence genomes of RSVA and RSVB. This enables researchers and public health agencies to acquire high-quality genomic data using rapid and cost-effective approaches. Genomic data-based comparative analysis can be used to conduct surveillance and monitor circulating isolates for efficacy of vaccines and antiviral therapeutics.
Motivation SARS-CoV-2 is the causative agent of the COVID-19 pandemic. Variants of Concern (VOCs) and Variants of Interest (VOIs) are lineages that represent a greater risk to public health, and can be differentiated from the wildtype virus based on unique profiles of signature mutations. Wastewater surveillance by metagenomic sequence analysis can capture signal for these variants that may not be detected by public health testing and/or sequencing initiatives. However, because multiple viral genomes are likely to be present in a metagenomic sample, additional analytical scrutiny of the sequencing reads beyond variant calling can provide more confident diagnostic determinations. Results We have developed MMMVI to aggregate and report cases where multiple mutations are present on a given read. These reads can be used as enhanced biomarkers to more confidently confirm the presence of a VOC/VOI in the sample. Availability MMMVI is implemented in Python, and is available under the MIT licence from https://github.com/dorbarker/voc-identify/ Contact dillon.barker{at}canada.ca
16 November 2026 in Influenza and Other Respiratory Viruses
Background: Seasonal influenza affects thousands of Canadians each year and places significant strain on workplaces and the health systems. Robust laboratory‐based surveillance is essential to monitor viral evolution and evaluate the suitability of medical countermeasures. Methods: The Canadian Influenza Surveillance Program characterizes circulating influenza viruses to determine genetic clades, monitor evolutionary trends, assess antigenicity and vaccine strain relatedness, and evaluate susceptibility to neuraminidase inhibitors. Methods include whole genome sequencing, hemagglutination inhibition assays, and neuraminidase inhibition assays. Results: From September 1, 2024 to August 31, 2025, the program antigenically characterized 1563 influenza isolates identified and submitted by Canadian laboratories. Of these, 99.4% of influenza A/H1N1, 86.6% of influenza A/H3N2, and 100% of influenza B isolates were antigenically related to their respective component of the 2024–2025 Northern Hemisphere vaccine. Genetic analysis of influenza A/H3N2 isolates identified three distinct mutation clustering patterns associated with reduced antigenic reactivity to the vaccine strain. Additionally, 1567 influenza viruses underwent antiviral susceptibility testing. Eleven influenza A/H1N1 isolates showed reduced inhibition to oseltamivir and two to zanamivir, all containing known resistance‐associated markers. Conclusions: These findings highlight the importance of comprehensive virological assessment, integrating genotypic and phenotypic data, to inform annual vaccine strain selection and support clinical decision‐making.